Cargando…

Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer

Pathogenic variants (PVs) in multiple genes are known to increase the risk of early-onset renal cancer (eoRC). However, many eoRC patients lack PVs in RC-specific genes; thus, their genetic risk remains undefined. Here, we determine if PVs in DNA damage response and repair (DDRR) genes are enriched...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartman, Tiffiney R., Demidova, Elena V., Lesh, Randy W., Hoang, Lily, Richardson, Marcy, Forman, Andrea, Kessler, Lisa, Speare, Virginia, Golemis, Erica A., Hall, Michael J., Daly, Mary B., Arora, Sanjeevani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419503/
https://www.ncbi.nlm.nih.gov/pubmed/32782288
http://dx.doi.org/10.1038/s41598-020-70449-5
_version_ 1783569897906765824
author Hartman, Tiffiney R.
Demidova, Elena V.
Lesh, Randy W.
Hoang, Lily
Richardson, Marcy
Forman, Andrea
Kessler, Lisa
Speare, Virginia
Golemis, Erica A.
Hall, Michael J.
Daly, Mary B.
Arora, Sanjeevani
author_facet Hartman, Tiffiney R.
Demidova, Elena V.
Lesh, Randy W.
Hoang, Lily
Richardson, Marcy
Forman, Andrea
Kessler, Lisa
Speare, Virginia
Golemis, Erica A.
Hall, Michael J.
Daly, Mary B.
Arora, Sanjeevani
author_sort Hartman, Tiffiney R.
collection PubMed
description Pathogenic variants (PVs) in multiple genes are known to increase the risk of early-onset renal cancer (eoRC). However, many eoRC patients lack PVs in RC-specific genes; thus, their genetic risk remains undefined. Here, we determine if PVs in DNA damage response and repair (DDRR) genes are enriched in eoRC patients undergoing cancer risk assessment. Retrospective review of de-identified results from 844 eoRC patients, undergoing testing with a multi-gene panel, for a variety of indications, by Ambry Genetics. PVs in cancer-risk genes were identified in 12.8% of patients—with 3.7% in RC-specific, and 8.55% in DDRR genes. DDRR gene PVs were most commonly identified in CHEK2, BRCA1, BRCA2, and ATM. Among the 2.1% of patients with a BRCA1 or BRCA2 PV, < 50% reported a personal history of hereditary breast or ovarian-associated cancer. No association between age of RC diagnosis and prevalence of PVs in RC-specific or DDRR genes was observed. Additionally, 57.9% patients reported at least one additional cancer; breast cancer being the most common (40.1% of females, 2.5% of males). Multi-gene testing including DDRR genes may provide a more comprehensive risk assessment in eoRC patients. Further validation is needed to characterize the association with eoRC.
format Online
Article
Text
id pubmed-7419503
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74195032020-08-13 Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer Hartman, Tiffiney R. Demidova, Elena V. Lesh, Randy W. Hoang, Lily Richardson, Marcy Forman, Andrea Kessler, Lisa Speare, Virginia Golemis, Erica A. Hall, Michael J. Daly, Mary B. Arora, Sanjeevani Sci Rep Article Pathogenic variants (PVs) in multiple genes are known to increase the risk of early-onset renal cancer (eoRC). However, many eoRC patients lack PVs in RC-specific genes; thus, their genetic risk remains undefined. Here, we determine if PVs in DNA damage response and repair (DDRR) genes are enriched in eoRC patients undergoing cancer risk assessment. Retrospective review of de-identified results from 844 eoRC patients, undergoing testing with a multi-gene panel, for a variety of indications, by Ambry Genetics. PVs in cancer-risk genes were identified in 12.8% of patients—with 3.7% in RC-specific, and 8.55% in DDRR genes. DDRR gene PVs were most commonly identified in CHEK2, BRCA1, BRCA2, and ATM. Among the 2.1% of patients with a BRCA1 or BRCA2 PV, < 50% reported a personal history of hereditary breast or ovarian-associated cancer. No association between age of RC diagnosis and prevalence of PVs in RC-specific or DDRR genes was observed. Additionally, 57.9% patients reported at least one additional cancer; breast cancer being the most common (40.1% of females, 2.5% of males). Multi-gene testing including DDRR genes may provide a more comprehensive risk assessment in eoRC patients. Further validation is needed to characterize the association with eoRC. Nature Publishing Group UK 2020-08-11 /pmc/articles/PMC7419503/ /pubmed/32782288 http://dx.doi.org/10.1038/s41598-020-70449-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Hartman, Tiffiney R.
Demidova, Elena V.
Lesh, Randy W.
Hoang, Lily
Richardson, Marcy
Forman, Andrea
Kessler, Lisa
Speare, Virginia
Golemis, Erica A.
Hall, Michael J.
Daly, Mary B.
Arora, Sanjeevani
Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
title Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
title_full Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
title_fullStr Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
title_full_unstemmed Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
title_short Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
title_sort prevalence of pathogenic variants in dna damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419503/
https://www.ncbi.nlm.nih.gov/pubmed/32782288
http://dx.doi.org/10.1038/s41598-020-70449-5
work_keys_str_mv AT hartmantiffineyr prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT demidovaelenav prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT leshrandyw prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT hoanglily prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT richardsonmarcy prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT formanandrea prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT kesslerlisa prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT spearevirginia prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT golemisericaa prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT hallmichaelj prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT dalymaryb prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer
AT arorasanjeevani prevalenceofpathogenicvariantsindnadamageresponseandrepairgenesinpatientsundergoingcancerriskassessmentandreportingapersonalhistoryofearlyonsetrenalcancer